Fludarabine

Drug Profile

Fludarabine

Alternative Names: 2-Fluoro-ARA-AMP; Beneflur; Fludara; Fludarabine phosphate; NSC 312887

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Southern Research Institute
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Arabinonucleosides; Myeloablative agonists; Purine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2014 Fludarabine licensed to Emcure Pharmaceuticals in India
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top